{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:30:04Z","timestamp":1793777404979,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Operations of Centralized High-level Chinese Medicine Hospitals","award":["CZ015"],"award-info":[{"award-number":["CZ015"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7242236"],"award-info":[{"award-number":["7242236"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aims to comprehensively evaluate the hematologic toxicity profiles, toxicity spectrum, and safety rankings of immune checkpoint inhibitors (ICIs) used for digestive system tumors. The PubMed, Cochrane Library, Web of Science, and Embase databases were systematically searched from inception to August 2024 to identify randomized controlled trials (RCTs). The primary outcome was anemia, while secondary outcomes included neutropenia, neutrophil count decreased, thrombocytopenia, platelet count decreased, leukopenia, white blood cell (WBC) count decreased, lymphocyte count decreased, and febrile neutropenia (FN). Subgroup analyses were performed based on tumor type, country category, study phase, ICI regimen, control group, chemotherapy regimen, ICI plus different chemotherapy regimens. Two reviewers independently selected the studies, extracted data according to pre-specified criteria, and assessed the risk of bias using the Cochrane Collaboration risk of bias tool. RevMan 5.4 software was utilized to visualize the risk of bias assessments. Stata 16.0 was used to conduct network meta-analysis, sensitivity analysis and meta-regression. 25 phase II and III RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915216) were included. The general safety of ICIs ranked from high to low for grade 1\u20135 anemia were as follows: avelumab, nivolumab, pembrolizumab, sintilimab, camrelizumab, and tislelizumab. For grade 3\u20135 anemia, the general safety profile of the ICIs were as follows, from highest to lowest: avelumab, nivolumab, pembrolizumab, sintilimab, and camrelizumab. Compared to chemotherapy, treatment-related hematologic toxicities with ICIs occurred primarily in grade 1\u20135 anemia, neutropenia, thrombocytopenia, leukopenia, and WBC count decreased. Taking ICI monotherapy, nivolumab plus ipilimumab were generally safer than taking chemotherapy, one ICI drug with chemotherapy, or two ICI drugs with chemotherapy. In terms of grade 1\u20135 hematologic toxicities, tislelizumab had the highest risk of neutropenia and leukopenia; the primary treatment-adverse events (AEs) for sintilimab was neutrophil count decreased and WBC count decreased; the primary treatment-related AE associated with nivolumab was platelet count decreased; camrelizumab posed the highest risk for lymphocyte count decreased. In terms of grade 3\u20135 hematologic toxicities, pembrolizumab was predominantly linked to neutropenia; sintilimab showed the greatest risk for neutrophil count decreased, platelet count decreased, and lymphocyte count decreased; avelumab was most associated with WBC count decreased. FN primarily manifested as grade 3\u20135, with camrelizumab having the highest risk. Among agents used in gastric or gastroesophageal junction cancer, avelumab demonstrated the most favorable safety profile for anemia. Each treatment regimen has its unique safety profile. Early identification and management of ICI-related hematologic toxicities are essential in clinical practice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Systematic Review Registration<\/jats:italic>\n                    : PROSPERO CRD42024571508.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01688-x","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:48:21Z","timestamp":1747158501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"25","author":[{"given":"Xinpu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suicai","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"1688_CR1","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","volume":"12","author":"P Tomassetti","year":"2001","unstructured":"Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12:S95\u20139.","journal-title":"Ann Oncol"},{"key":"1688_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4614-6625-3_49-1","volume-title":"Handbook of Epidemiology","author":"A Timmer","year":"2019","unstructured":"Timmer A. Epidemiology of Digestive Diseases. In: Ahrens W, Pigeot I, editors. Handbook of Epidemiology. New York, NY: Springer New York; 2019. p. 1\u201345. https:\/\/doi.org\/10.1007\/978-1-4614-6625-3_49-1."},{"issue":"10","key":"1688_CR3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346\u201353.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1688_CR4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","volume":"11","author":"TC Gangadhar","year":"2014","unstructured":"Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11(2):91\u20139.","journal-title":"Nat Rev Clin Oncol"},{"key":"1688_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","volume":"99","author":"S Tabchi","year":"2016","unstructured":"Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer. 2016;99:123\u20136.","journal-title":"Lung Cancer"},{"key":"1688_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7\u201316.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1688_CR7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"issue":"5","key":"1688_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","volume":"14","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437\u201348.","journal-title":"Expert Rev Hematol"},{"issue":"36","key":"1688_CR9","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1688_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","author":"X Cheng","year":"2018","unstructured":"Cheng X, Chen Y-P, Xiao-Jing D, Liu J-Q, Huang C-L, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018. https:\/\/doi.org\/10.1136\/bmj.k4226.","journal-title":"BMJ"},{"key":"1688_CR11","doi-asserted-by":"crossref","first-page":"1163971","DOI":"10.3389\/fphar.2023.1163971","volume":"14","author":"J Hou","year":"2023","unstructured":"Hou J, Xie R, Zhang Z, Liu Q, Xiang Q, Cui Y. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials. Front Pharmacol. 2023;14:1163971.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1688_CR12","doi-asserted-by":"publisher","first-page":"W-65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, et al. The Prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W-65-W\u221294. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00136.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1688_CR13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The Prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"1688_CR14","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Chandler","year":"2019","unstructured":"Chandler J, Cumpston M, Li T, Page MJ, Welch V. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: Wiley; 2019."},{"key":"1688_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","volume":"83","author":"A Chaimani","year":"2017","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. J Clin Epidemiol. 2017;83:65\u201374.","journal-title":"J Clin Epidemiol"},{"key":"1688_CR16","doi-asserted-by":"crossref","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39:e2017047.","journal-title":"Epidemiol Health"},{"key":"1688_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2914","author":"EJ Mills","year":"2013","unstructured":"Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ. 2013. https:\/\/doi.org\/10.1136\/bmj.f2914.","journal-title":"BMJ"},{"issue":"4","key":"1688_CR18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/jrsm.1270","volume":"8","author":"G R\u00fccker","year":"2017","unstructured":"R\u00fccker G, Schwarzer G. Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments. Res Synthe Methods. 2017;8(4):526\u201336.","journal-title":"Res Synthe Methods"},{"issue":"10","key":"1688_CR19","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","volume":"29","author":"Y-J Bang","year":"2018","unstructured":"Bang Y-J, Ruiz EY, Van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, et al. Phase Iii, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of javelin gastric 300. Ann Oncol. 2018;29(10):2052\u201360.","journal-title":"Ann Oncol"},{"issue":"5","key":"1688_CR20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.34019","volume":"128","author":"HC Chung","year":"2022","unstructured":"Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (keynote-063): a randomized, open-label, phase 3 trial in Asian patients. Cancer. 2022;128(5):995\u20131003.","journal-title":"Cancer"},{"issue":"5","key":"1688_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"17","key":"1688_CR22","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al. First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase ii relativity-060 study. J Clin Oncol. 2024;42(17):2080\u201393.","journal-title":"J Clin Oncol"},{"issue":"10294","key":"1688_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/oesophageal adenocarcinoma (checkmate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet (London, England). 2021;398(10294):27.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"1688_CR24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (attraction-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1688_CR25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage Iii gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (attraction-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1688_CR26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J-N, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"1688_CR27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin C-Y, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (attraction-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"10391","key":"1688_CR28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (keynote-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391):1853\u201365.","journal-title":"The Lancet"},{"issue":"35","key":"1688_CR29","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, et al. Randomized phase Iii keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1688_CR30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou A, Liu S, He M, Chen K, Tian Z, et al. Comparing a Pd-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced Escc: a randomized phase Ii clinical trial: a randomized clinical trial of neoadjuvant therapy for Escc. BMC Med. 2023;21(1):86.","journal-title":"BMC Med"},{"key":"1688_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (orient-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022. https:\/\/doi.org\/10.1136\/bmj-2021-068714.","journal-title":"BMJ"},{"issue":"10","key":"1688_CR32","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the escort-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"issue":"11","key":"1688_CR33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for Her2-negative advanced gastric cancer (Keynote-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1688_CR34","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim S-B, Ajani JA, Zhao K, He Z, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (rationale-302): a randomized phase Iii study. J Clin Oncol. 2022;40(26):3065\u201376.","journal-title":"J Clin Oncol"},{"issue":"10142","key":"1688_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, Di Bartolomeo M, Mandal\u00e0 M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (keynote-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392(10142):123\u201333.","journal-title":"The Lancet"},{"issue":"10","key":"1688_CR36","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1688_CR37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","volume":"29","author":"Y Song","year":"2023","unstructured":"Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, et al. First-line serplulimab or placebo plus chemotherapy in Pd-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29(2):473\u201382.","journal-title":"Nat Med"},{"issue":"10302","key":"1688_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (keynote-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"The Lancet"},{"issue":"3","key":"1688_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"Z-X Wang","year":"2022","unstructured":"Wang Z-X, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (jupiter-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277-288.e3. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"1688_CR40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","volume":"13","author":"J Xu","year":"2022","unstructured":"Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (orient-2). Nat Commun. 2022;13(1):857.","journal-title":"Nat Commun"},{"issue":"21","key":"1688_CR41","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"issue":"5","key":"1688_CR42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (rationale-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1688_CR43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (escort): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"key":"1688_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2021.04.001","volume":"509","author":"B Luo","year":"2021","unstructured":"Luo B, Zhang Y, Zhang C, Liu X, Shi C. Intestinal microbiota: a potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Lett. 2021;509:53\u201362.","journal-title":"Cancer Lett"},{"issue":"11","key":"1688_CR45","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4251\/wjgo.v12.i11.1346","volume":"12","author":"L Yang","year":"2020","unstructured":"Yang L, Dong X-Z, Xing X-X, Cui X-H, Li L, Zhang L. Efficacy and safety of anti-Pd-1\/anti-Pd-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: a meta-analysis. World J Gastroint Oncol. 2020;12(11):1346.","journal-title":"World J Gastroint Oncol"},{"issue":"2","key":"1688_CR46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"2","key":"1688_CR47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2496","volume":"14","author":"PT Sage","year":"2013","unstructured":"Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor Pd-1 controls follicular regulatory t cells in the lymph nodes and blood. Nat Immunol. 2013;14(2):152\u201361.","journal-title":"Nat Immunol"},{"issue":"1","key":"1688_CR48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21\u201333.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"1688_CR49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21(7):495\u2013508.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1688_CR50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior J, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31(9):1273\u20135.","journal-title":"Ann Oncol"},{"issue":"6","key":"1688_CR51","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020;31(6):724\u201344.","journal-title":"Ann Oncol"},{"issue":"1","key":"1688_CR52","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immuno Therapy Cancer. 2020;8(1):e000604. https:\/\/doi.org\/10.1136\/jitc-2020-000604.","journal-title":"J Immuno Therapy Cancer"},{"issue":"21","key":"1688_CR53","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2169\/internalmedicine.5922-20","volume":"60","author":"M Yomota","year":"2021","unstructured":"Yomota M, Mirokuji K, Sakaguchi M, Kitahara Y, Chin F, Setoguchi K, et al. Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-small-cell lung cancer. Intern Med. 2021;60(21):3459\u201362.","journal-title":"Intern Med"},{"issue":"23","key":"1688_CR54","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"issue":"6","key":"1688_CR55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.20102538","volume":"208","author":"EE Zoller","year":"2011","unstructured":"Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011;208(6):1203\u201314.","journal-title":"J Exp Med"},{"issue":"3","key":"1688_CR56","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.4049\/jimmunol.175.3.1464","volume":"175","author":"N Felli","year":"2005","unstructured":"Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C, et al. Multiple members of the Tnf superfamily contribute to Ifn-\u0393-mediated inhibition of erythropoiesis. J Immunol. 2005;175(3):1464\u201372.","journal-title":"J Immunol"},{"issue":"9","key":"1688_CR57","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2010-10-315218","volume":"118","author":"SF Libregts","year":"2011","unstructured":"Libregts SF, Guti\u00e9rrez L, de Bruin AM, Wensveen FM, Papadopoulos P, van Ijcken W. Chronic IFN-\u03b3 production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1\/PU.1 axis. Blood. 2011;118(9):2578\u201388. https:\/\/doi.org\/10.1182\/blood-2010-10-315218.","journal-title":"Blood"},{"issue":"25","key":"1688_CR58","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2014-01-549527","volume":"124","author":"F-C Lin","year":"2014","unstructured":"Lin F-C, Karwan M, Saleh B, Hodge DL, Chan T, Boelte KC, et al. Ifn-\u0393 causes aplastic anemia by altering hematopoietic stem\/progenitor cell composition and disrupting lineage differentiation. Blood. 2014;124(25):3699\u2013708. https:\/\/doi.org\/10.1182\/blood-2014-01-549527.","journal-title":"Blood"},{"issue":"19","key":"1688_CR59","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.3390\/ijms231911740","volume":"23","author":"D Jarczak","year":"2022","unstructured":"Jarczak D, Nierhaus A. Cytokine storm\u2014definition, causes, and implications. Int J Mol Sci. 2022;23(19):11740.","journal-title":"Int J Mol Sci"},{"issue":"6371","key":"1688_CR60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of Pd-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"1688_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut Microbiome affects the response to anti-pd-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7:1\u20137.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1688_CR62","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804\u20138.","journal-title":"Nat Med"},{"issue":"17","key":"1688_CR63","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.3390\/nu14173478","volume":"14","author":"IJ Malesza","year":"2022","unstructured":"Malesza IJ, Bartkowiak-Wieczorek J, Winkler-Galicki J, Nowicka A, Dzi\u0119cio\u0142owska D, B\u0142aszczyk M, et al. The dark side of iron: the relationship between iron, inflammation and gut microbiota in selected diseases associated with iron deficiency anaemia\u2014a narrative review. Nutrients. 2022;14(17):3478.","journal-title":"Nutrients"},{"key":"1688_CR64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10637-019-00845-w","volume":"38","author":"S Refae","year":"2020","unstructured":"Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, et al. Germinal immunogenetics predict treatment outcome for Pd-1\/Pd-L1 checkpoint inhibitors. Invest New Drugs. 2020;38:160\u201371.","journal-title":"Invest New Drugs"},{"key":"1688_CR65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","volume":"130","author":"S Yano","year":"2020","unstructured":"Yano S, Ashida K, Sakamoto R, Sakaguchi C, Ogata M, Maruyama K, et al. Human leucocyte antigen Dr15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198\u2013203.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1688_CR66","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, et al. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019;24(5):584\u20138.","journal-title":"Oncologist"},{"key":"1688_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Cr B, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (sitc) toxicity management working group. J Immuno Therapy Cancer. 2017. https:\/\/doi.org\/10.1186\/s40425-017-0300-z.","journal-title":"J Immuno Therapy Cancer"},{"key":"1688_CR68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733890","volume":"12","author":"K Hradska","year":"2021","unstructured":"Hradska K, Hajek R, Jelinek T. Toxicity of immune-checkpoint inhibitors in hematological malignancies. Front Pharmacol. 2021;12: 733890.","journal-title":"Front Pharmacol"},{"key":"1688_CR69","doi-asserted-by":"crossref","first-page":"1213608","DOI":"10.3389\/fphar.2023.1213608","volume":"14","author":"N Li","year":"2023","unstructured":"Li N, Feng Y, Chen X, Li Y, Zhang C, Yin Y. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study. Front Pharmacol. 2023;14:1213608.","journal-title":"Front Pharmacol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01688-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:27Z","timestamp":1764917427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01688-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01688-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"157"}}